Core Laboratories Inc. /DE/
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
CLB$8.84-1.0%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets at June 30, 2026 (Unaudited) and December 31, 2025
CONSOLIDATED BALANCE SHEETS
| June 30,2026 | December 31,2025 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $22,735 | $22,702 |
| Accounts receivable, net of allowance for credit losses of $6,504 and $6,317 at 2026 and 2025, respectively | 108,817 | 113,528 |
| Inventories | 57,961 | 54,496 |
| Prepaid expenses | 10,953 | 9,734 |
| Income taxes receivable | 7,265 | 7,270 |
| Other current assets | 6,629 | 6,935 |
| TOTAL CURRENT ASSETS | 214,360 | 214,665 |
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $318,900 and $320,707 at 2026 and 2025, respectively | 100,390 | 99,447 |
| RIGHT OF USE ASSETS | 52,870 | 54,346 |
| INTANGIBLES, net of accumulated amortization and impairment of $19,879 and $19,531 at 2026 and 2025, respectively | 6,752 | 7,118 |
| GOODWILL | 105,796 | 105,789 |
| DEFERRED TAX ASSETS, net | 70,574 | 67,381 |
| OTHER ASSETS | 36,036 | 35,264 |
| TOTAL ASSETS | $586,778 | $584,010 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $40,163 | $37,275 |
| Accrued payroll and related costs | 21,736 | 26,525 |
| Taxes other than payroll and income | 3,509 | 4,272 |
| Unearned revenues | 5,076 | 5,552 |
| Operating lease liabilities | 11,940 | 11,456 |
| Income taxes payable | 1,615 | 4,255 |
| Other current liabilities | 17,011 | 16,680 |
| TOTAL CURRENT LIABILITIES | 101,050 | 106,015 |
| LONG-TERM DEBT, net | 113,861 | 110,255 |
| LONG-TERM OPERATING LEASE LIABILITIES | 39,314 | 42,309 |
| DEFERRED COMPENSATION | 29,938 | 29,381 |
| DEFERRED TAX LIABILITIES, net | 7,553 | 7,995 |
| OTHER LONG-TERM LIABILITIES | 16,293 | 15,847 |
| COMMITMENTS AND CONTINGENCIES | ||
| EQUITY: | ||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | — | — |
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,966,868 issued and 45,884,100 outstanding at 2026; 46,966,868 issued and 46,095,379 outstanding at 2025 | 470 | 470 |
| Additional paid-in capital | 115,512 | 110,245 |
| Retained earnings | 176,909 | 172,662 |
| Accumulated other comprehensive income (loss) | (5,678) | (5,806) |
| Treasury stock (at cost), 1,082,768 and 871,489 shares at 2026 and 2025, respectively | (14,544) | (11,585) |
| Total Core Laboratories Inc. shareholders' equity | 272,669 | 265,986 |
| Non-controlling interest | 6,100 | 6,222 |
| TOTAL EQUITY | 278,769 | 272,208 |
| TOTAL LIABILITIES AND EQUITY | $586,778 | $584,010 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.